The ATON System uses multi-laser optical spectroscopy to quantify molecules
Unlike conventional lab tests, the ATON System does not use chemistry. Advanced lasers excite the molecules in the sample. Sensors collect molecular signatures from scattered light. The software reports the concentrations of each target in the test panel. Real-time results inform personalized treatment decisions for better outcomes, improved patient satisfaction and reduced costs.
Any new medical device needs to satisfy an unmet need or fill a clinical gap to be successful. More than ever before, healthcare innovators must align with the “Triple Aim” shared by providers and payors: Improve health outcomes, enhance patient satisfaction and reduce costs.
At Atonarp, we strive to meet the Triple Aim challenge with our diagnostic tests by delivering actionable results that inform time-critical decisions to improve the lives of patients, their families and the providers who care for them.
Atonarp is developing tests to inform the care team on dialysis adequacy, anemia, bone health and nutritional status so treatment can be personalized for each patient.
Patients with end stage renal disease have lost their kidney function and need dialysis or a kidney transplant to stay alive. Most patients go to dialysis centers three times per week for 3 to 4-hour sessions to remove toxins and excess water from their blood. Treatment is rough… side effects are common and many patients take hours to recover after a session.
The care team needs better tools to optimize dialysis prescriptions and personalize treatment for these challenging patients.
Get actionable lab results on site rather than sending blood to a reference lab
Rapid results enable the care team to adjust the dialysis prescription and medications sooner
Patients feel better. Optimized treatment means fewer hospital days and lower costs.
Atonarp plans to develop tests to assess patients with symptoms of heart attack.
• Over 10 million Americans go to the emergency department with chest pain each year. Although only 13% of them have had a heart attack, but 66% are admitted to the hospital.
• Implementing testing with a high sensitivity troponin test can increase discharge rate from 34% to 75%, which could save $7 billion per year.
Troponin leaks from dead heart cells. It is used to diagnose heart attack.
Safely discharge low-risk patients or admit patients with heart attack faster.
Discharging patients quickly eases crowding in the ED and allows efficient care of more patients.
Atonarp plans to develop point-of-care, multiplex tests for inflammatory and sepsis biomarkers in blood.
Inflammatory biomarkers are associated with severe infection and sepsis and can be measured early in acute infection. Research indicates that certain combinations of these biomarkers may be prognostic for “cytokine storm,” which is an out-of-control immune response that is associated with bad outcomes in COVID-19 and sepsis. Our panels will provide rapid results that may give insights about immune response and help inform treatment decisions.
Speed matters. Sepsis can progress rapidly and can be fatal. Each hour of delay in giving antibiotics increases risk of death by 7%.
Costs $27 billion annually in the U.S.
Sepsis affects 30 million people worldwide and causes 6 million deaths annually.
Atonarp is developing our multi-laser optical spectroscopy technology for non-invasive, transdermal measurement of glucose to monitor patients with diabetes.
Non-invasive testing replaces fingersticks
Modify diet, exercise and medications
Better control improves outcomes and reduces costs